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Abstract 
We investigated the incidence of non-embolic adverse events in 2 cohorts of AF patients and 
validated the 2MACE score [(metabolic syndrome, age ≥75) [doubled]; (myocardial 
infarction (MI)/revascularization, congestive heart failure (HF) and 
stroke/TIA/thromboembolism)] as predictor of major adverse cardiovascular events 
(MACEs). We recruited 2630 AF patients from two different cohorts (Murcia AF and 
FANTASIIA). The 2MACE score was calculated and during a median of 7.2 years (Murcia 
AF cohort) and 1.01 years (FANTASIIA) of follow-up we recorded all non-embolic adverse 
events and MACEs (composite of non-fatal MI/revascularization and cardiovascular death). 
ROC curves comparison, reclassification/ discriminatory analyses and decision curve 
analysis, were performed to compare predictive ability and clinical usefulness of 2MACE 
score against CHA2DS2-VASc. During follow-up, there were 65 MACEs in the Murcia 
cohort and 60 in FANTASIIA. Events rates were higher in the high risk category (score ≥3) 
(1.94%/year vs. 0.81%/year in the Murcia cohort; 6.01%/year vs. 1.71%/year, in 
FANTASIIA, both p<0.001). The predictive performance of 2MACE according to the ROC 
curve was significantly higher from that of CHA2DS2-VASc (0.662 vs. 0.618, p=0.008 in the 
Murcia cohort; 0.656 vs. 0.565, p=0.003 in FANTASIIA). Decision curve analyses 
demonstrated improved clinical usefulness of the 2MACE compared to the CHA2DS2-VASc 
score. In conclusion, in ‘real world’ AF patients, the 2MACE score is a good predictor of 
MACEs. A score ≥3 should be used to categorize patients at ‘high risk’, in identifying 
patients at risk of MACE. 
 
Keywords: atrial fibrillation, myocardial infarction, mortality, risk assessment. 
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Introduction 
Recently, the 2MACE score [2 points for Metabolic Syndrome and Age ≥75, and 1 
point for Myocardial Infarction/revascularization, Congestive heart failure (ejection fraction 
≤40 %) and thrombo-Embolism (stroke/TIA)] has been described to stratify cardiovascular 
risk in non-valvular AF patients. According to this clinical tool, patients with a score ≥3 (high 
risk) have a risk almost 4-fold higher of suffering a cardiovascular adverse event.
1
 Thus, this 
score may provide new information that would optimize the management and treatment of 
patients with AF, with important implications for clinical practice. In the present study, we 
investigated the incidence of non-embolic thrombotic adverse events in two ‘real world’ 
cohorts of AF patients. In addition we validated the 2MACE score as predictor of major 
adverse cardiovascular events (MACEs) in both populations, in comparison with the 
CHA2DS2-VASc score. 
 
Methods  
From May 1, 2007 to December 1, 2007 in our single anticoagulation center in a 
tertiary hospital in Murcia (South-east Spain), we included consecutive patients with 
paroxysmal/permanent non-valvular AF who were stable with VKA (INR 2.0-3.0) for at least 
the previous 6 months. At entry, all patients were receiving anticoagulation therapy with 
acenocoumarol (the commonest VKA used in Spain) and consistently achieved an INR 
between 2.0 and 3.0 during the previous 6 months. This inclusion criterion guarantees 
baseline homogeneity, and avoided any influence of fluctuant INR. For the same reason, we 
also excluded patients with rheumatic mitral valves or prosthetic heart valves, as well as 
those with any acute coronary syndrome, stroke, hemodynamic instability, hospital 
admissions or surgical interventions in the preceding 6 months in the present analysis. In this 
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cohort, follow-up was performed through routine visits to the anticoagulation clinic and 
through medical records. Importantly, no patient was lost to follow-up. 
In addition, we also included consecutive AF patients from the FANTASIIA (Spanish 
acronym for “Fibrilación Auricular: influencia del Nivel y Tipo de Anticoagulación Sobre la 
Incidencia de Ictus y Accidentes hemorrágicos”) registry. This registry is an observational, 
multicenter, national and prospective study of the general characteristics and current situation 
of a Spanish non-valvular AF population between June 2013 and March 2014. Patients 
enrolled in FANTASIIA were receiving anticoagulant therapy (VKA or Non-vitamin K Oral 
Anticoagulants [NOAC]) for at least 6 months before enrolment, and were followed in 50 
outpatient clinics by 81 investigators. The follow-up was carried out in three visits, at 1, 2 
and 3 years. At each visit, clinical and laboratory data were collected from patients. 
At baseline, stroke risk (CHA2DS2-VASc) and bleeding risk (HAS-BLED) were 
calculated in these two cohorts, and a complete medical history was recorded. The time in 
therapeutic range (TTR) was calculated at 6 month after entry in both populations according 
to the Rosendaal method. The 2MACE score was also calculated at baseline, as described by 
Pastori et al.
1
 For defining the metabolic syndrome (MetS), we used the established definition 
of the World Health Organization (WHO).
2, 3
 
The primary endpoints were MACEs (the composite of nonfatal myocardial infarction 
[MI]/cardiac revascularization and cardiovascular death [death caused by sudden death, 
progressive congestive heart failure, fatal MI or procedure-related death]), and these were 
recorded during the follow-up period. We excluded from MACE all embolic events; i.e. 
stroke/transient ischaemic attack and peripheral embolism were not included. The 
investigators identified, confirmed and recorded all adverse events and outcomes. 
The study protocol was approved by the Ethics Committee from University Hospital 
Morales Meseguer and performed in accordance with the ethical standards laid down in the 
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1964 Declaration of Helsinki and its later amendments. All patients gave informed consent to 
participation in the study. 
Categorical variables were expressed as frequencies and percentages. Continuous 
variables were presented as median and interquartile range (IQR), or mean ± standard 
deviation (SD) if distribution was normal according to the Kolmogorov-Smirnov test. Cox 
proportional hazard regression models were used to determine the association between higher 
values of the 2MACE score and MACE. Survival analyses by Kaplan-Meier estimates were 
performed to assess differences in event-free survival distributions between subgroups of 
cardiovascular risk categories. Finally, receiver operating characteristic (ROC) curve were 
carried out to evaluate the predictive ability (expressed as c-index) of the 2MACE score. 
Comparisons of ROC curves between 2MACE score and CHA2DS2-VASc score were carried 
out by the DeLong et al. method.
4
 Additionally, we used the methods described by Zhou et 
al.
5
 for calculating the weighted summary area under the ROC curve under the fixed effects 
model and random effects model. Integrated discriminatory improvement (IDI) and net 
reclassification improvement (NRI) were performed according to the methods described by 
Pencina et al.
6
 Finally, clinical usefulness and net benefit of the 2MACE score in comparison 
with CHA2DS2-VASc were estimated using decision curve analysis (DCA).
7, 8
 
In all analyses, p values <0.05 were accepted as statistically significant. Statistical 
analyses were performed using SPSS v. 19.0 for Windows (SPSS, Inc., Chicago, IL, USA), 
MedCalc v. 16.4.3 (MedCalc Software bvba, Ostend, Belgium), and STATA v. 12.0 (Stata 
Corp., College Station, TX, USA) for Windows. 
 
Results 
Baseline clinical characteristics are shown in Table 1. We included 693 patients (49.6% 
male; median age 75, IQR 69-80 years) followed-up for a median of 7.2 years (IQR 6.2-7.9) 
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from our AF cohort and 1937 patients (55.8% male; mean age 73.84 ± 9.48 years) followed-
up for a median of 1.01 years (IQR 0.99-1.05) from FANTASIIA registry. CHA2DS2-VASc 
and HAS-BLED were calculated at entry, with median values of 4 (IQR 3-5) and 2 (IQR 2-
3), respectively in our cohort and 4 (IQR 3-5) and 2 (IQR 1-3) in the FANTASIIA registry. 
The median TTR at 6 months after inclusion was 80% (IQR 66-100) and 63.03 (IQR 43.3-80) 
in both, our population and FANTASIIA. Baseline clinical characteristics associated with the 
development of a MACE during follow-up are shown in Supplementary Tables 1 and 2. 
During the follow-up, 58 patients from our population suffered from a stroke (8.4%, i.e. 
1.16%/year) and 106 suffered from a major bleeding event (15.3%, 2.12%/year). In the 
FANTASIIA registry, 15 patients had a stroke (0.77%/year) while 65 suffered from a major 
bleeding event (3.36%/year). In this period there were 65 MACE (9.4%; 1.30%/year) in our 
cohort. Of these, 31 (4.5%, 0.62%/year) were cardiovascular deaths and 34 (4.9%, 
0.68%/year) were non-fatal MI/revascularizations. Regarding the FANTASIIA cohort, 60 
patients suffered a MACE (3.10%; 3.06%/year); 38 (2%; 1.94%/year) were cardiovascular 
deaths and 22 (1.4%; 1.12%/year) were non-fatal MI/revascularizations (Table 2).  
When we calculated the 2MACE score as described by Pastori et al.,
1
 the median value 
in our cohort was 2 (IQR 1-3), and 300 patients (43.3%) had a score ≥3 (i.e. high risk). In the 
FANTASIIA registry, we found a median 2MACE score of 2 (IQR 0-3) and 610 patients 
(31.5%) with a score ≥3. In our cohort, patients with 2MACE score ≥3 suffered 42 MACEs, 
which resulted into an annual event rate of 1.94%/year for this group. In the population of 
FANTASIIA, 37 patients with 2MACE score ≥3 suffered a MACE (6.01%/year). Cox 
regression analysis performed in our cohort showed that patients categorized as high risk 
(score ≥3) had significantly higher risk of MACE (HR 2.88, 95% CI 1.73-4.80; p<0.001) 
(Supplementary Figure 1). The overall risk for each score point was 1.50 (95% CI 1.30-1.74, 
p<0.001) in our cohort, and 1.52 (95% CI 1.28-1.80, p<0.001) in the FANTASIIA registry. 
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ROC curve analysis demonstrated that the 2MACE score had a good performance for 
predict MACE in AF patients of our cohort, with a c-index of 0.662 (95% CI 0.625-0.697, 
p<0.001). This analysis showed the 2MACE score >2 as the best combination of sensitivity 
(64.6%) and specificity (60.0%). The cohort of the FANTASIIA registry showed similar 
results and the 2MACE score had a c-index of 0.656 (95% CI 0.593-0.719, p<0.001), with 
the score ≥3 presenting the best combination of sensitivity (61.7 %) and specificity (69.5%). 
Comparisons of the ROC curves of 2MACE and CHA2DS2-VASc scores proved that 
the 2MACE score had better predictive ability for predict MACE, both, in our Murcia cohort 
(0.662 vs. 0.618, p=0.008) and in the FANTASIIA cohort (0.656 vs. 0.565, p=0.003) (Table 
3, Supplementary Figure 2). Additionally, the weighted summary area under the ROC curve 
under the fixed effects model and random effects model, also demonstrated a good 
performance of the 2MACE for predict MACE, even including the internal derivation and the 
external validation cohorts of Pastori et al. into the models (fixed effects: 0.668; 95% CI 
0.641-0.696; random effects: 0.674; 95% CI 0.634-0.715, both p<0.001) (Figure 1).  
Reclassification analyses showed significant improvement in sensitivity and important 
positive reclassification of the 2MACE score compared with the CHA2DS2-VASc score, 
based on the IDI and NRI (Table 3).  
Finally, decision curve analyses (DCA) graphically demonstrates that the overall risk of 
MACE in the MURCIA AF cohort was approximately 9%, according to the intersection of 
the y-axis and the slanted dash grey line. In the FANTASIIA population, the overall risk was 
around 30%. In both cohorts, as the lines of the 2MACE score are farthest away from the 
slanted dash grey lines (i.e., assume all MACE) and the horizontal black lines (i.e., assume 
none MACE), the 2MACE score demonstrates improved clinical usefulness and a higher net 
benefit compared to the CHA2DS2-VASc score (Figure 2). 
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Discussion 
In this first study validating the 2MACE score in ‘real world’ patients taking both, 
VKA and NOACs, we show that this novel score has a moderate predictive performance for 
MACEs in two different cohorts of AF patients.  
Patients with AF are under a high risk of ischemic stroke and mortality.
9-12
 Our study 
confirms that other adverse cardiovascular events are frequent in these patients, with an 
incidence close to 3%/year in a population taking VKAs or NOACs, a rate which is even 
higher than that for stroke. This has been highlighted in previous studies that show that AF is 
associated with a risk of myocardial infarction due to the coexistence of atherosclerotic risk 
factors and is associated with the presence of some biomarkers also present in patients with 
coronary heart disease.
13-19
 
Given this information, it seems useful to have a simple clinical risk score to easily 
classify those AF patients at increased risk of cardiovascular events.
20
 As well as CHA2DS2-
VASc and HAS-BLED are widely used in clinical practice to estimate, respectively, the risk 
of ischemic stroke and bleeding, the new 2MACE score has proved to be useful for predicting 
MACE, with implications for clinical practice by aiding decision-making about 
antithrombotic therapies. 
We have also compared the predictive ability for MACE of CHA2DS2-VASc and 
2MACE scores. In previous studies, the predictive performance for non-stroke events of the 
CHA2DS2-VASc score has been investigated, and has proved to be useful predicting non-
embolic adverse cardiovascular events.
21-25
 Although in this study the CHA2DS2-VASc score 
remained a modest c-index for MACE, the 2MACE score demonstrates significantly better 
predictive performance for these events. In addition, this novel score demonstrates better 
discrimination and reclassification ability, as well as higher net benefit and clinical usefulness 
in comparison with CHA2DS2-VASc.  
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In the present study, in our both cohorts of patients, the 2MACE score had a similar c-
index as the external validation cohort of Pastori et al. (i.e., 0.66). Indeed, a score >2 in the 
Murcia AF cohort showed the best combination of sensitivity and specificity while in the 
original article by Pastori et al. the best combination was obtained by a score ≥3,1 as was also 
confirmed in the FANTASIIA cohort. Importantly, we show that the 2MACE score can be 
useful in two different contexts. First, in AF patients taking VKA or NOAC from a 
multicenter registry in the short-term follow-up. Second, in AF patients well-controlled with 
VKA and during a long-term follow-up period. These observations potentially add value to 
this novel score for use in daily clinical practice.  
This study has several limitations that should be noted. First, the Murcia AF cohort is a 
Caucasian based population from a single centre. Second, all patients were treated with VKA 
(INR 2.0-3.0) during the previous 6 months to ensure homogeneity at baseline. We 
acknowledge that this inclusion criterion may not reflect ‘typical’ clinical practice, but the 
long follow-up and the standard care received make this cohort suitable. The FANTASIIA 
observational registry includes patients taking VKA or NOAC and its design is multicenter. 
However, individual incidence rates of MACE presents in this study may be low, since the 
follow-up is yet only of 1 year and the planned complete follow-up for three years is ongoing. 
Although our datasets were collected prospectively, all statistical analyses were performed 
retrospectively. This led us to define the MetS according to the WHO criteria, since at the end 
of follow-up we did not have the waist circumference of all patients.  
 
In conclusion, in ‘real world’ AF patients, the 2MACE score is a good predictor of 
MACE. A score ≥3 should be used to categorize patients at ‘high risk’, in identifying patients 
at risk of MACE.  
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Figure 1. Weighted summary area under the receiver operating characteristic curve. 
Figure 2. Decision curves for the 2MACE and CHA2DS2-VASc scores. 
This analysis shows the clinical usefulness of each score based on a continuum of potential 
thresholds for major adverse cardiovascular events (x-axis) and the net benefit of using the 
model to stratify patients at risk (y-axis) relative to assuming that no patient will have a major 
adverse cardiovascular event. 
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Table 1. Baseline clinical characteristics. 
Variables 
MURCIA AF  
(N = 693) 
FANTASIIA  
(N = 1937) 
 
Age (years), median (IQR)/mean (SD) 75 (69-80) 73.84 ± 9.48 
Men 344 (49.6%) 1080 (55.8%) 
Body-mass index (kg/m
2
), median (IQR)/mean (SD) 75 (69-80) 28.95 ± 4.83 
Hypertension 564 (81.4%) 1559 (80.5%) 
Diabetes mellitus 166 (24.0%) 565 (29.2%) 
Metabolic syndrome 170 (24.5%) 1047 (54.1%) 
Heart failure 206 (29.7%) 561 (29.0%) 
Coronary artery disease 139 (20.1%) 350 (18.1%) 
Hypercholesterolemia 258 (37.2%)  1528 (78.9%) 
Current smoking habit 104 (15.0%) 97 (5.0%) 
History of stroke/TIA/thromboembolism 119 (17.2%) 329 (17.0%) 
Hepatic impairment 5 (0.7%) 23 (1.2%) 
Renal impairment 70 (10.1%) 376 (19.4%) 
 
Previous medications 
 
 
Amiodarone 41 (5.9%) 240 (12.4%) 
Digoxin 126 (18.2%) 353 (18.2%) 
Beta-blockers 245 (35.4%) 1170 (60.4%) 
ACE inhibitors /ARBs 370 (53.4%) 1387 (71.6%) 
Calcium channel blockers 178 (25.7%) 467 (24.1%) 
Diuretics 303 (43.7%) 1112 (57.4%) 
Antiplatelets 127 (18.3%) 207 (10.7%) 
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Statins 187 (27.0%) 1065 (55.0%) 
 
TTR (%) at 6 months, median (IQR) 80 (66-100) 63.03 (43.3-80) 
CHA2DS2-VASc score, median (IQR) 4 (3-5) 4 (3-5) 
HAS-BLED score, median (IQR) 2 (2-3) 2 (1-3) 
2MACE score, median (IQR) 2 (1-3) 2 (0-3) 
ACE inhibitors = angiotensin-converting-enzyme inhibitors; ARBs = angiotensin II receptor 
blockers; IQR = interquartile range; SD = standard deviation; TIA = transient ischemic 
attack; TTR = time in therapeutic range. 
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Table 2. Distribution of major adverse cardiovascular events according to the cardiovascular risk categories. 
 MURCIA AF cohort FANTASIIA cohort 
  2MACE score   2MACE score  
 
Total 
(n = 693) 
score < 3 
(n = 393) 
score ≥ 3 
(n = 300) 
p 
Total 
(n = 1937) 
score < 3 
 (n = 1327) 
score ≥ 3 
 (n = 610) 
p 
 
MACE 65 (9.4%) 23 (5.9%) 42 (14.0%) 
<0.001 
60 (3.1%) 23 (1.7%) 37 (6.1%) 
<0.001 
annual rate (%/year) 1.30%/year 0.81%/year 1.94%/year 3.06%/year 1.71%/year 6.01%/year 
Non-fatal 
MI/revascularization 
34 (4.9%) 13 (3.3%) 21 (7.0%) 
0.026 
22 (1.4%) 11 (0.8%) 11 (1.8%) 
0.110 
annual rate (%/year) 0.68%/year 0.46%/year 0.97%/year 1.12%/year 0.82%/year 1.79%/year 
Cardiovascular death 31 (4.5%) 10 (2.5%) 21 (7.0%) 
0.005 
38 (2.0%) 12 (0.9%) 26 (4.3%) 
<0.001 
annual rate (%/year) 0.62%/year 0.35%/year 0.97%/year 1.94%/year 0.89%/year 4.22%/year 
 
MACE = major adverse cardiovascular event; MI = myocardial infarction. 
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Table 3. Comparison of the receiver operating characteristic curves, integrated discriminatory improvement and net reclassification 
improvement of the CHA2DS2-VASc and 2MACE scores. 
 C-index 95% CI p* IDI p NRI p 
MURCIA AF cohort 
 
2MACE  0.662 0.625-0.697 0.008 0.0188 <0.001 0.2517 <0.001 
CHA2DS2-VASc 0.618 0.581-0.655      
 
FANTASIIA cohort 
 
2MACE  0.656 0.593-0.719 0.003 0.0110 <0.001 0.3720 0.002 
CHA2DS2-VASc 0.565 0.526-0.605      
 
CI = confidence interval; IDI = integrated discriminatory improvement; NRI = net reclassification improvement. *for c-index comparison.  
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